gp100:209-217(210M)

BIOLOGICAL2 trials

Sponsors

National Cancer Institute (NCI), H. Lee Moffitt Cancer Center and Research Institute

Conditions

Melanoma (Skin)Recurrent MelanomaStage IA MelanomaStage IB MelanomaStage IIA MelanomaStage IIB MelanomaStage IIC MelanomaStage IIIA Melanoma

Phase 1

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

CompletedNCT01176461

H. Lee Moffitt Cancer Center and Research InstituteMelanoma (Skin)

Start: 2010-08-04End: 2016-12-12Updated: 2023-01-18

Phase 2

Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

CompletedNCT00003895

National Cancer Institute (NCI)Recurrent Melanoma, Stage IA Melanoma, Stage IB Melanoma +6

Start: 1999-04-30End: 2013-09-30Updated: 2017-02-20

Related Papers

The Reality of Precision Medicine in Metastatic Melanoma

Oncology Times2018-03-13

Abstract 4891: A mass spectrometry-based serum test to predict outcome of treatment with nivolumab: Analysis of samples taken during therapy

Cancer Research2016-07-153 citations

Survival, biomarker, and toxicity analysis of nivolumab (NIVO) in patients that progressed on ipilimumab (IPI).

Journal of Clinical Oncology2015-05-2015 citations

Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, ipilimumab (IPI).

Journal of Clinical Oncology2014-05-2014 citations